Handok Exclusively Sells Roche's Chronic Kidney Disease Anemia Treatment
Handok said that it began the exclusive sales of Mircera, Roche's chronic kidney disease anemia treatment, on Jan. 1, in Korea.
Mircera (ingredient name: methoxypolyethylene glycol-epoetin beta) is a third-generation erythrocyte hematopoietic stimulator to treat symptomatic anemia in patients with chronic kidney disease.
As the world's first continuous erythropoietin receptor activator, it has accumulated clinical data for more than 10 years and has confirmed its safety and effectiveness. It has improved treatment compliance and convenience, as hospitals can administer the drug once a month by dramatically improving the half-life while maintaining hemoglobin levels stably.
Mircera extended the half-life of the first-generation epoetin beta (ESA), from 48 hours to 139 hours by combining polyethylene glycol, which increases the half-life of pharmaceuticals, and first-generation ESA, according to Handok.
"We are glad that Mircera with an innovative mechanism can help treat anemia in patients with chronic kidney disease," Handok CEO Kim Young-jin said. "Handok recently established a separate organization to strengthen the competitiveness of its kidney treatments, and will continue to strengthen its expertise by expanding products."
Roche Korea CEO Nic Horridge also said, "We are delighted to form a new partnership with Handok, which has been collaborating with us in various diseases."
Through this partnership, the company expects Handok to deliver the benefits of Mircera more quickly and widely to more Korean chronic renal disease symptomatic anemia patients, Horrdige added.